富瑞特裝(300228.SZ):鄔品芳累計減持517.22萬股 持股降至5%以下
格隆匯1月7日丨富瑞特裝(300228.SZ)公佈,近日,公司收到鄔品芳出具的《關於減持公司股份的告知函》。2020年1月6日,鄔品芳通過深圳證券交易所集中競價交易減持股份149.22萬股,減持股份總數符合減持計劃約定的股數,減持計劃已實施完畢。鄔品芳並於2019年5月13日至2019年5月30日通過深圳證券交易所集中競價交易減持公司股份368.00萬股,綜上,鄔品芳合計減持公司股份517.22萬股,佔公司總股本的1.09409%
此次減持後,鄔品芳持有股份2363.7萬股,佔公司總股本比例4.99998%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.